Highly cited cancer papers, 2008–2010

highly cited cancer papers, 2008–2010The following tables show the primary research papers on cancer published between 2008 and 2010 that have had the highest number of citations in the literature. To create these tables, we queried the Scopus database) to search for articles that included the term ‘cancer’ or related terms in the title, abstract or keywords. After sorting the results on the basis of citation number, we removed reviews and epidemiological studies. The predominance of genomic studies in these tables is remarkable. The number of citations is accurate as of 8 February 2010. The tables include papers that have been cited at least 250 (2008 table), 125 (2009 table) and 35 (2010 table) times.
Highly cited cancer research published in 2008
Llovet, J.M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390.
Amado, R.G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26,
McLendon, R. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455,
Parsons, D.W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812.
Mani, S.A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715.
Karapetis, C.S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765.
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806.
Lièvre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetux- imab. J. Clin. Oncol. 26, 374–379.
Scagliotti, G.V. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive
patients with advanced-stage non–small-cell lung cancer. J. Clin. Oncol. 26, 3543–3551.
Motzer, R.J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456.
Saltz, L.B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013–2019.
Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598.
Feng, H. et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096–1100.
Gregory, P.A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593–601.
Tavazoie, S.F. et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147–152.
Thorgeirsson, T.E. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452,
Hung, R.J. et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452,
Amos, C.I. et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40,
Mitchell, P.S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105,
Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46.
Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705–5712.
Ben-Porath, I. et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat.
Genet. 40, 499–507.
Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075.
Qian, X. et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat. Biotech. 26,
De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal can- cer treated with cetuximab. Ann. Oncol. 19, 508–515.
Asangani, I.A. et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion,
intravasation and metastasis in colorectal cancer. Oncogene 27, 2128–2136.
volume 17 | number 3 | march 2011 NAture medIcINe
Highly cited cancer research published in 2009
Schröder, F.H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360,
Berg, C.D. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–
Mok, T.S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957.
Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408–1417.
Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J.
Med. 361, 123–134.
Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion
and distant metastasis. Cancer Cell 15, 220–231
Lippman, S.M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium
and vitamin E cancer prevention trial (SELECT). J. Am. Med. Assoc. 301, 39–51.
Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non–small-cell lung cancer (FLEX): an
open-label randomised phase III trial. Lancet 373, 1525–1531.
Ebos, J.M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell 15, 232–239.
Tol, J. et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360,
Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671.
Reck, M. et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy
for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol. 27, 1227–1234.
Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360,
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773.
Cheng, A.-L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocel- lular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34.
Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910–914.
Baxter, N.N. et al. Association of colonoscopy and death from colorectal cancer. Ann. Internal Med. 150, 1–8.
Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608–611.
Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466.
Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361,
Hecht, J.R. et al. A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672–680.
Motzer, R.J. et al. Overall survival and updated results for sunitinib compared with interferon a in patients with
metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590.
Paavonen, J. et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infec-
tion and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study
in young women. Lancet 374, 301–314.
Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137,
Irizarry, R.A. et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178–186.
Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of
colitis-associated cancer. Cancer Cell 15, 103–113.
Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-
targeted monoclonal antibodies. Cancer Res. 69, 1851–1857.
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301.
Gupta, P.B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138,
Kim, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457,
NAture medIcINe volume 17 | number 3 | march 2011
Highly cited cancer research published in 2010
Pleasance, E.D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191–196.
Pleasance, E.D. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184–190.
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905.
Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the epider- mal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121–128.
Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723.
Heidorn, S.J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221.
Verhaak, R.G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17, 98–110.
Sternberg, C.N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin.
Oncol. 28, 1061–1068.
Poulikakos, P.I. et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430.
Ward, P.S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-keto- glutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234.
Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435.
Rajkumar, S.V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29–37.
Andriole, G.L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192–1202.
Bonner, J.A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 ran- domised trial, and relation between cetuximab-induced rash and survival.
Lancet Oncol. 11, 21–28.
Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819.
Atkin, W.S. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375, 1624–1633.
Davis, M.E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070.
Maemondo, M. et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388.
et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55–65.
Dalgliesh, G.L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360–363.
Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005.
Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80.
Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185.
Gupta, R.A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071–1076.
Douillard, J.-Y. et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the randomized phase III INTEREST trial. J. Clin. Oncol. 28, 744–752.
Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62–73.
Wacholder, S. et al. Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362, 986–993.
Roth, A.D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28, 466–474.
Yao, J.C. et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemo-
therapy: a phase II trial. J. Clin. Oncol. 28, 69–76.
Park, E.J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140,
Folprecht, G. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 11, 38–47.
volume 17 | number 3 | march 2011 NAture medIcINe

Source: http://swyy.czstb.gov.cn/Upload/Attach/20110314095214-highly%20cited%20cancer%20papers,2008-2010.PDF

Kardecian spiritist federation of florida, inc

FEDERACIÓN ESPIRITISTA KARDECIANA DA LA FLORIDA, INC. (FEKDFLA) P.O. BOX 526822 – Miami, Florida 33151, U.S.A. “ESTATUTOS” DE LA FEDERACIÓN ESPIRITISTA KARDECIANA DE LA Capítulo I Del Nombre, Constitución y Jurisdicción Art. 1 – La agrupación (no lucrativa) que por estos Estatutos se regula, se donomina KARDECIAN SPIRITIST FEDERATION OF FLORIDA INCORPORATED (Federación E

Rakel & bope_section-14

Rakel & Bope_Section-14 10/29/03 12:55 PM Page 959 TREATMENT OF TOURETTE’S 5. Use of stimulants . Because stimulants can maketics worse, it is often assumed that stimulants are con- SYNDROME traindicated in the treatment of TS. In reality, the ticsare often mild and easy to treat, and it is the co-morbidADHD that causes the greatest disability. Failureto address and treat the ADHD

Copyright © 2010-2014 Internet pdf articles